Why MannKind Stock Soared 19% Higher on Tuesday
The biotech delivered quite an impressive earnings report.
Stay updated with breaking news from Michael Castagna. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The biotech delivered quite an impressive earnings report.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices
MannKind (NASDAQ:MNKD – Get Free Report) is scheduled to announce its earnings results after the market closes on Monday, August 7th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link. MannKind (NASDAQ:MNKD – Get […]
Hunter Associates Investment Management LLC grew its position in shares of MannKind Co. (NASDAQ:MNKD – Free Report) by 31.1% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 50,570 shares of the biopharmaceutical company’s stock after buying an additional 12,000 shares during the quarter. […]
MannKind Co. (NASDAQ:MNKD – Free Report) – Equities researchers at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for MannKind in a report released on Tuesday, July 11th. Cantor Fitzgerald analyst O. Brayer anticipates that the biopharmaceutical company will earn $0.09 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating […]